The Enterprise Value as of November 2024 (TTM) for Denali Therapeutics Inc. (DNLI) is 3.52B

According to Denali Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.52B. This represents a change of -3.30% compared to the average of 3.64B of the last 4 quarters.

Denali Therapeutics Inc. (DNLI) Historical Enterprise Value (quarterly & annually)

How has DNLI Enterprise Value performed in the past?

The mean historical Enterprise Value of Denali Therapeutics Inc. over the last ten years is 2.63B. The current 3.52B Enterprise Value has changed 13.24% with respect to the historical average. Over the past ten years (40 quarters), DNLI's Enterprise Value was at its highest in in the December 2020 quarter at 9.62B. The Enterprise Value was at its lowest in in the March 2016 quarter at 0.

Denali Therapeutics Inc. (DNLI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Denali Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Denali Therapeutics Inc. (DNLI) Average Enterprise Value

How has DNLI Enterprise Value performed in the past?

The current Enterprise Value of Denali Therapeutics Inc. (DNLI) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Denali Therapeutics Inc. (DNLI) Enterprise Value vs. Peers

How is DNLI’s Enterprise Value compared to its peers?

Denali Therapeutics Inc.’s Enterprise Value is greater than Homology Medicines, Inc. (-103303255.00), greater than Stoke Therapeutics, Inc. (457.69M), greater than Atreca, Inc. (-8620212.00), greater than Black Diamond Therapeutics, Inc. (139.97M), greater than 4D Molecular Therapeutics, Inc. (197.41M), less than Ascendis Pharma A/S (7.61B), less than Apellis Pharmaceuticals, Inc. (3.90B), less than BeiGene, Ltd. (19.75B), greater than Akero Therapeutics, Inc. (2.00B), less than Blueprint Medicines Corporation (6.36B), less than Legend Biotech Corporation (7.40B), less than Vaxcyte, Inc. (10.01B), greater than Travere Therapeutics, Inc. (1.95B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Avidity Biosciences, Inc. (4.80B), less than Revolution Medicines, Inc. (9.43B), greater than Day One Biopharmaceuticals, Inc. (963.46M), greater than SpringWorks Therapeutics, Inc. (2.83B), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Design Therapeutics, Inc. (290.40M), greater than Werewolf Therapeutics, Inc. (-1378920.00), greater than Ikena Oncology, Inc. (45.73M),

Build a custom stock screener for Denali Therapeutics Inc. (DNLI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Denali Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Denali Therapeutics Inc. (DNLI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Denali Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.